CSIMarket
 
Celgene Corp  (CELG)
Other Ticker:  
 
 

Celgene's Suppliers Performance

CELG's Supply Chain

 
CELG Costs vs Sales of Suppliers Growth Revenues of Celgene's Suppliers, deteriorated by -18.85 % compared to the same quarter a year ago, from the previous quarter, sales fell by -9.31 %, Celgene recorded an increase in cost of sales by 6.37 % year on year, sequentially cost of sales grew by 10.6 % in Q3.

More on CELG Suppliers




Celgene's Suppliers realized a deteriorated in sales by -18.85 % compared to the same quarter a year ago, from the previous quarter, sales fell by -9.31 %, Celgene recorded increase in cost of sales by 6.37 % year on year, sequentially cost of sales grew by 10.6 % in Q3.

More on CELG Suppliers



  News about Celgene Corp Contracts



Celgene's Comment on Supply Chain


We own and operate an FDA approved manufacturing facility in Zofingen, Switzerland which produces the active pharmaceutical ingredient (API) for REVLIMID® and THALOMID® and have contracted with FDA approved third-party contract manufacturers to provide backup API manufacturing services for these products. Manufacturing services for REVLIMID® and THALOMID®, which consist of formulation, encapsulation, packaging, warehousing and distribution, are performed at our FDA approved drug product manufacturing facility in Boudry, Switzerland. We have contracted with a number of third-party drug product manufacturing service providers and packaging service providers to provide backup manufacturing and packaging services. All of our third-party service providers are approved by the regulatory authorities for the geographies that they serve.

The API for ABRAXANE® is generally available from multiple sources and is normally available in quantities adequate to meet our needs. Manufacturing services for ABRAXANE® are performed at our manufacturing facility in Arizona and by an approved third party contract manufacturing facility.

The API for VIDAZA® is supplied by three suppliers. Manufacturing and packaging services are provided by a number of third-party service providers.
The API for the azacitidine for injection (generic version of VIDAZA®) is supplied by a single -source supplier. Manufacturing and packaging services are provided by a single manufacturer.

The API for POMALYST®/IMNOVID® is supplied by a single-source supplier with primary manufacturing services being performed at our Boudry manufacturing facility.We have contracted with a number of third-party drug product manufacturing service providers and packaging service providers to provide backup manufacturing and packaging services for this product.

The API for ISTODAX® is supplied by a single-source supplier. Manufacturing and packaging services are provided by a number of third-party service providers.
The API for OTEZLA® (apremilast) is supplied by two suppliers with manufacturing services being performed at our Boudry manufacturing facility. We expect to utilize third-party service providers for backup manufacturing and packaging services for this product.

The API for FOCALIN® and FOCALIN XR® is currently obtained from two suppliers, and we rely on a single manufacturer for the tableting and packaging of FOCALIN® finished product.